A Phase I/II Trial to Evaluate the Safety and Tolerability of Clazakizumab (Anti-IL-6 Monoclonal) As an Agent to Eliminate Donor Specific HLA Antibodies and Improve Outcomes of Patients With Chronic & Active Antibody-Mediated Rejection Post-Kidney Transplantation
Status: Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 05 Jun 2019
Price : $35 *
At a glance
- Drugs Clazakizumab (Primary)
- Indications Renal transplant rejection
- Focus Therapeutic Use
- 07 Mar 2019 Planned End Date changed from 31 Oct 2020 to 31 Dec 2020.
- 07 Mar 2019 Planned primary completion date changed from 31 Dec 2019 to 31 Mar 2020.
- 07 Mar 2019 Status changed from recruiting to active, no longer recruiting.